The estimated Net Worth of Claire Fraser is at least $7.34 millió dollars as of 28 August 2023. Ms. Fraser owns over 848 units of Becton Dickinson & Co stock worth over $5,049,574 and over the last 18 years she sold BDX stock worth over $1,939,964. In addition, she makes $351,224 as Independent Director at Becton Dickinson & Co.
Sign up
Ms. Fraser BDX stock SEC Form 4 insiders trading
Claire has made over 8 trades of the Becton Dickinson & Co stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 848 units of BDX stock worth $238,848 on 28 August 2023.
The largest trade she's ever made was selling 1,500 units of Becton Dickinson & Co stock on 11 February 2020 worth over $388,080. On average, Claire trades about 173 units every 34 days since 2007. As of 28 August 2023 she still owns at least 21,608 units of Becton Dickinson & Co stock.
You can see the complete history of Ms. Fraser stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Claire Fraser biography
Claire M. Fraser Ph.D serves as Independent Director of the Company. Since 2007, she has been Director of the Institute for Genome Sciences and a Professor of Medicine at the University of Maryland School of Medicine in Baltimore, Maryland. From 1998 to 2007, she served as President and Director of The Institute for Genomic Research, a not-for-profit center dedicated to deciphering and analyzing genomes. Dr. Fraser is the President-Elect of the American Association for the Advancement of Science (AAAS), and also serves on the Board of AAAS and Ohana Biosciences Inc. Dr. Fraser is a prominent scientist with a strong background in infectious diseases and molecular diagnostics, including the development of novel diagnostics and vaccines. She also brings considerable managerial experience in her field.
What is the salary of Claire Fraser?
As the Independent Director of Becton Dickinson & Co, the total compensation of Claire Fraser at Becton Dickinson & Co is $351,224. There are 16 executives at Becton Dickinson & Co getting paid more, with Vincent Forlenza having the highest compensation of $16,014,600.
How old is Claire Fraser?
Claire Fraser is 64, she's been the Independent Director of Becton Dickinson & Co since 2006. There are 8 older and 25 younger executives at Becton Dickinson & Co. The oldest executive at Becton Dickinson & Co. is Marshall Larsen, 71, who is the Lead Independent Director.
What's Claire Fraser's mailing address?
Claire's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Becton Dickinson & Co
Over the last 22 years, insiders at Becton Dickinson & Co have traded over $106,782,599 worth of Becton Dickinson & Co stock and bought 23,860 units worth $1,771,828 . The most active insiders traders include Edward J Ludwig, William M Brown és Vincent A Forlenza. On average, Becton Dickinson & Co executives and independent directors trade stock every 20 days with the average trade being worth of $4,349,205. The most recent stock trade was executed by Roland Goette on 14 August 2024, trading 5,295 units of BDX stock currently worth $701,799.
What does Becton Dickinson & Co do?
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.
What does Becton Dickinson & Co's logo look like?
Complete history of Ms. Fraser stock trades at Seres Therapeutics Inc és Becton Dickinson & Co
Becton Dickinson & Co executives and stock owners
Becton Dickinson & Co executives and other stock owners filed with the SEC include:
-
Vincent Forlenza,
Executive Chairman of the Board -
Patrick Kaltenbach,
Executive Vice President, President - Life Sciences -
Thomas Polen,
President, Chief Executive Officer, Chief Operating Officer, Director -
Christopher Reidy,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer -
Alberto Mas,
Executive Vice President, President - Medical Segment -
Thomas E. Polen Jr.,
Pres, CEO & Chairman -
Samrat Khichi,
Executive Vice President - Public Policy and Regulatory Affairs -
Alexandre Conroy,
Executive Vice President, Chief Integrated Supply Chain Officer -
Vincent A. Forlenza,
Exec. Chairman -
Samrat S. Khichi,
Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel -
Alberto Mas,
Exec. VP & Pres of the Medical Segment -
Samrat S. Khichi Esq.,
Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel -
Christopher R. Reidy,
Exec. VP, CFO & Chief Admin. Officer -
Simon D. Campion,
Exec. VP & Pres of Interventional Segment -
Christopher DelOrefice,
Exec. VP & CFO -
Marshall Larsen,
Lead Independent Director -
Bertram Scott,
Independent Director -
Claire Fraser,
Independent Director -
Christopher Jones,
Independent Director -
Catherine Burzik,
Independent Director -
Claire Pomeroy,
Independent Director -
Timothy Ring,
Independent Director -
Rebecca Rimel,
Independent Director -
David Melcher,
Independent Director -
Jeffrey Henderson,
Independent Director -
R. Andrew Eckert,
Independent Director -
John DeFord,
Executive Vice President, Chief Technology Officer -
James Lim,
Executive Vice President, President, Greater Asia -
Thomas Spoerel,
Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller -
Monique Dolecki,
Investor Relations Contact Officer -
Charles Bodner,
Senior Vice President, Corporate Finance -
Roland Goette,
Executive Vice President, President - EMEA -
Simon Campion,
Executive Vice President and President, BD Interventional Segment -
Betty Larson,
Executive Vice President- Human Resources, Chief Human Resources -
Denise Fleming,
Exec. VP of Technology & Global Services and Chief Information Officer -
Francesca M. DeMartino,
Sr. VP of Investor Relations -
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.,
Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board -
Troy Kirkpatrick,
VP of PR -
Elizabeth McCombs,
Exec. VP & Chief Technology Officer -
Michelle Quinn,
Sr. VP and Chief Ethics & Compliance Officer -
Jerry Flasz,
Exec. VP of Global Services & Chief Information Officer -
Dr. John A. DeFord,
Exec. VP of R&D and CTO -
Thomas J. Spoerel,
Sr. VP, Controller & Chief Accounting Officer -
Joanne Waldstreicher,
Director -
Gary A Mecklenburg,
Director -
John E Gallagher,
VP, Corp Finance and Treasurer -
Linda M Tharby,
Segment Pres. Life Sciences -
Wilard J Jr Overlock,
Director -
Nabil Shabshab,
Senior Vice President -
Jeffrey S Sherman,
VP and General Counsel -
Basil Anderson,
Director -
Ellen R Strahlman,
Senior Vice President -
James F Orr,
Director -
William A Tozzi,
VP and Controller -
Gary M Cohen,
President - BD Medical Systems -
Stephen Sichak,
Senior Vice President -
Henry P Jr Becton,
Director -
Carrie L Byington,
Director -
Edward Degraan,
Director -
William A Kozy,
Pres - BD CLS and Cmpy Oper -
Alfred Sommer,
Director -
David Shan,
EVP and Chief ISC Officer -
Shana Carol Neal,
EVP and Chief People Officer -
John P Groetelaars,
EVP -
James W Borzi,
EVP & Chief Supply Chain Offcr -
Suketu Upadhyay,
Senior VP and Controller -
Adel Mahmoud,
Director -
Jerome V Hurwitz,
Senior Vice President -
Donna M Boles,
Sr. Exec VP - Human Resources -
David V Elkins,
Executive VP and CFO -
David T Durack,
Senior Vice President -
William E. Rhodes,
Senior Vice President -
Joseph Mercurio,
VP and Corporate Controller -
Patricia B Shrader,
Senior Vice President -
Scott P Bruder,
SrVP; Chief Technology Officer -
Cathy E. Minehan,
Director -
Margeretha Af Ugglas,
Director -
Edward J Ludwig,
Chairman, President and CEO -
James E Perrella,
Director -
Alfred John Hanson,
Executive Vice President -
John R Considine,
Executive VP and CFO -
Jean Marc Dageville,
VP - Human Resources -
Harry N Beaty,
Director -
Frank Albert Olson,
Director -
Bridget M Healy,
VP, Gen Counsel and Secy -
Christopher Del Orefice,
EVP & Chief Financial Officer -
Antoine C Ezell,
EVP, President NA & CMO -
David Hickey,
EVP & President, Life Sciences -
William M Brown,
Director -
Rishi Grover,
EVP and Chief ISC Officer -
Michael David Garrison,
EVP & President Medical -
Richard Byrd,
EVP & President Interventional -
Pavan Kumar Mocherla,
EVP & President Greater Asia -
Michael Feld,
EVP & President, Life Sciences